Overview
flowchart TD
companies_daewoong_pharmaceuti["Daewoong Pharmaceutical"]
style companies_daewoong_pharmaceuti fill:#4fc3f7,stroke:#333,color:#000
companies_daewoong_p_0["Company Profile"]
companies_daewoong_pharmaceuti -->|"includes"| companies_daewoong_p_0
style companies_daewoong_p_0 fill:#81c784,stroke:#333,color:#000
companies_daewoong_p_1["History and Milestones"]
companies_daewoong_pharmaceuti -->|"includes"| companies_daewoong_p_1
style companies_daewoong_p_1 fill:#ef5350,stroke:#333,color:#000
companies_daewoong_p_2["Business Segments"]
companies_daewoong_pharmaceuti -->|"includes"| companies_daewoong_p_2
style companies_daewoong_p_2 fill:#ffd54f,stroke:#333,color:#000
companies_daewoong_p_3["Pharmaceutical Division"]
companies_daewoong_pharmaceuti -->|"includes"| companies_daewoong_p_3
style companies_daewoong_p_3 fill:#ce93d8,stroke:#333,color:#000
companies_daewoong_p_4["Biotechnology Division"]
companies_daewoong_pharmaceuti -->|"includes"| companies_daewoong_p_4
style companies_daewoong_p_4 fill:#4fc3f7,stroke:#333,color:#000
companies_daewoong_p_5["Global Business"]
companies_daewoong_pharmaceuti -->|"includes"| companies_daewoong_p_5
style companies_daewoong_p_5 fill:#81c784,stroke:#333,color:#000
...Overview
Mermaid diagram (expand to render)
Daewoong Pharmaceutical Co., Ltd. (KOSPI: 003690) is a leading South Korean pharmaceutical company headquartered in Seongnam, South Korea. Founded in 1932, Daewoong has evolved from a traditional pharmaceutical manufacturer into a diversified healthcare company with significant focus on advanced therapies, including cell therapy, gene therapy, and innovative small molecules for neurodegenerative diseases. The company represents one of Korea's largest domestic pharmaceutical players and has been actively expanding its global footprint through strategic partnerships and international market entry["@daewoong"].
Company Profile
| Attribute | Details |
|-----------|---------|
| Company Name | Daewoong Pharmaceutical Co., Ltd. |
| Headquarters | Seongnam, Gyeonggi-do, South Korea |
| Founded | 1932 |
| CEO | Lee Seung-ho |
| Stock Exchange | KOSPI |
| Ticker | 003690 |
| Revenue | ~$1.5B USD (2023) |
| Employees | ~3,000 |
| Focus | Pharmaceuticals, cell therapy, global expansion |
History and Milestones
| Year | Milestone |
|------|-----------|
| 1932 | Founded as Korean Pharmaceutical Company |
| 1970s | Major expansion of generic drug portfolio |
| 2000 | Entered biopharmaceuticals business |
| 2010 | Established cell therapy R&D center |
| 2015 | First overseas acquisition (US) |
| 2020 | Expanded into gene therapy |
| 2022 | Major partnership for Parkinson's cell therapy |
| 2023 | Global clinical trials for DW-5905 |
Business Segments
Pharmaceutical Division
Daewoong's core pharmaceutical business encompasses:
- Generic pharmaceuticals: Broad portfolio covering cardiovascular, metabolic, CNS, and oncology
- Novel drugs: In-house developed compounds in clinical development
- Contract manufacturing: OEM production for global pharma companies
Biotechnology Division
The biotechnology arm focuses on:
- Cell therapy: Stem cell-based treatments for degenerative diseases
- Gene therapy: Viral vector-based approaches for genetic disorders
- Biosimilars: Follow-on biologics for key therapeutic areas
Global Business
International operations include:
- subsidiaries in the US, Europe, and Asia
- Licensing agreements with major pharmaceutical companies
- Export of generic and specialty pharmaceuticals
Neurodegeneration Pipeline
Parkinson's Disease Programs
| Drug | Mechanism | Stage | Notes |
|------|-----------|-------|-------|
| DW-5905 | Dopamine D1/D2 receptor agonist | Phase 2 | Oral, long-acting formulation |
| DW-6302 | Cell therapy (mesenchymal stem cells) | Preclinical | IND-enabling for 2025 |
| DW-7101 | MAO-B inhibitor | Phase 1 | Novel formulation |
DW-5905 is Daewoong's lead Parkinson's disease program, designed as a新一代 dopamine receptor agonist with improved receptor selectivity and longer duration of action compared to existing treatments. The compound aims to provide better motor symptom control while reducing dyskinesia side effects[@daewoonga].
Alzheimer's Disease Programs
| Drug | Mechanism | Stage | Notes |
|------|-----------|-------|-------|
| DW-7801 | BACE1 inhibitor | Discovery | Program halted due to safety concerns |
| DW-8201 | Anti-amyloid monoclonal antibody | Preclinical | Partnership with US biotech |
| DW-8501 | Tau aggregation inhibitor | Discovery | Early research |
Other CNS Programs
| Drug | Indication | Stage |
|------|------------|-------|
| DW-9101 | ALS | Discovery |
| DW-9202 | Multiple sclerosis | Phase 1 |
Research Focus
Daewoong Pharmaceutical's neuroscience division maintains focus on several key areas:
Small Molecule Therapies
- Dopamine receptor agonists: Novel compounds targeting D1, D2, and D3 receptors with improved selectivity
- Enzyme inhibitors: MAO-B, COMT inhibitors for Parkinson's disease
- Neuroprotective agents: Compounds targeting oxidative stress, neuroinflammation
Cell Therapy
Daewoong has invested significantly in stem cell technology for neurodegenerative diseases:
- Mesenchymal stem cells (MSCs): For Parkinson's disease and ALS
- Neural stem cells: For Alzheimer's disease
- Induced pluripotent stem cells (iPSCs): Personalized cell therapy approaches
Novel Drug Delivery
- Blood-brain barrier penetration: Enhanced delivery systems for CNS drugs
- Sustained release formulations: Long-acting injections for improved compliance
- Combination therapies: Multi-target approaches for complex diseases
Key Products
Approved Products in Korea
| Product | Indication | Notes |
|---------|------------|-------|
| Nexlet® | Parkinson's disease (Levodopa/Carbidopa) | Leading domestic brand |
| Dexedrine® | ADHD | Market leader in Korea |
| Cureith® | Antidepressant | SNRI class |
| Daewoong products | Various | Broad CNS portfolio |
Market Position
Daewoong holds a significant share of the Korean pharmaceutical market, particularly in:
- CNS therapeutics (top 3 in Korea)
- Cardiovascular drugs
- Anti-diabetic medications
Global Strategy and Partnerships
Daewoong has pursued international expansion through multiple pathways:
Strategic Partnerships
| Partner | Focus | Type |
|---------|-------|------|
| Unknown US biotech | Anti-amyloid antibody | Co-development |
| Japanese pharma | Parkinson's cell therapy | Licensing |
| European company | Generic CNS drugs | Distribution |
International Expansion
- United States: Established subsidiary in 2015, expanding clinical operations
- Europe: Seeking marketing authorization for key products
- Southeast Asia: Distribution partnerships in key markets
M&A Activity
Daewoong has pursued acquisitions to accelerate its pipeline:
- US biotech acquisitions for advanced therapies
- European generic companies for market access
| Metric | Value (2023) |
|--------|--------------|
| Revenue | ~$1.5B USD |
| Operating Profit | ~$150M USD |
| R&D Investment | ~$200M (~13% of revenue) |
| Market Cap | ~$2B USD |
| KOSPI | 003690 |
Competitive Landscape
In the Korean market, Daewoong competes with:
- Samsung Bioepis: Biosimilars focus
- Celltrion: Biopharmaceuticals
- Hanmi Pharmaceutical: CNS and oncology
- Dong-A ST: Cardiovascular and CNS
Globally, Daewoong positions itself as a partner for Asian market access and a competitor in the cell therapy space.
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Cell Therapy](/therapies/cell-therapy)
- [Korean Biotech Companies](/companies/korean-neurodegeneration-biotech)
External Links
- [Daewoong Pharmaceutical Website](https://www.daewoong.co.kr)
- [Daewoong Pipeline](https://www.daewoong.co.kr/pipeline)
- [KOSPI: 003690](https://www.kospi.co.kr)
References
[Daewoong Pharmaceutical Corporate Website](https://www.daewoong.co.kr)
[Daewoong Pharmaceutical Pipeline](https://www.daewoong.co.kr/pipeline)
[Daewoong IR Materials](https://www.daewoong.co.kr/ir)
[KOSPI Company Profile](https://www.kospi.co.kr)